Sebetralstat
Clinical data | |
---|---|
Trade names | Ekterly |
Other names | KVD-900, KVD900 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H26FN5O4 |
Molar mass | 491.523 g·mol−1 |
3D model (JSmol) | |
| |
|
Sebetralstat, sold under the brand name Ekterly, is a medication used for the treatment of hereditary angioedema.[1] Sebetralstat is a plasma kallikrein inhibitor.[1]
Sebetralstat was approved for medical use in the United States in July 2025.[1][2]
Medical uses
Sebetralstat is indicated for the treatment of acute attacks of hereditary angioedema.[1]
Pharmacology
Sebetralstat is a plasma kallikrein inhibitor that contains the unusual 2-pyridone heterocycle.[3]
Society and culture
Legal status
Sebetralstat was approved for medical use in the United States in July 2025.[1] The US Food and Drug Administration granted the application for sebetralstat orphan drug designation.[4]
Names
Sebetralstat is the international nonproprietary name.[5]
Sebetralstat is sold under the brand name Ekterly.[1]
References
- ^ a b c d e f g "Ekterly- sebetralstat tablet". DailyMed. 7 July 2025. Retrieved 9 July 2025.
- ^ "KalVista Pharmaceuticals Announces FDA Approval of Ekterly (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema" (Press release). Kalvista. 7 July 2025. Retrieved 9 July 2025 – via Business Wire.
- ^ Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, et al. (October 2022). "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema". Journal of Medicinal Chemistry. 65 (20): 13629–13644. doi:10.1021/acs.jmedchem.2c00921. PMC 9620001. PMID 36251573.
- ^ "Sebetralstat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Retrieved 9 July 2025.
- ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.
External links
- "Sebetralstat (Code - C184930)". EVS Explore.
- Clinical trial number NCT05259917 for "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)" at ClinicalTrials.gov